GNPX
GNPX clinical trials: Genprex, Inc.
Every trial on ClinicalTrials.gov where Genprex, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
GNPX on the catalyst calendar · GNPX registry changes
- Primary completion Mar 2028Sponsor estimatePhase 1/Phase 2NCT04486833Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibGenprex, Inc. · Carcinoma, Non-Small Cell LungRecruitingGNPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT05703971Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC PatientsGenprex, Inc. · Small Cell Lung Cancer Extensive StageRecruitingGNPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 3, 2025ActualPhase 1NCT05062980Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerGenprex, Inc. · Non Small Cell Lung CancerTerminatedGNPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2016ActualPhase 1/Phase 2NCT01455389TUSC2-nanoparticles and Erlotinib in Stage IV Lung CancerGenprex, Inc. · Lung CancerTerminatedGNPXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner